Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 18.42% is 27% above its 5-year average of 14.49%, around the middle of its 5-year range (0.99%–32.85%).
As of the fiscal period ended Wednesday, December 31, 2025. 5.49% below its 12-month average of 19.49%.
Reported quarterly debt to assets ratio; no daily interpolation. Q4 FY2025 (2025-12-31): 18.42%.
DEBT TO ASSETS RATIO
18.42%
DEBT TO ASSETS RATIO AVG TTM
19.49%
DEBT TO ASSETS RATIO AVG 3Y
18.79%
DEBT TO ASSETS RATIO AVG 5Y
14.49%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-5.49%
CURRENT VS 3Y AVG
-1.95%
CURRENT VS 5Y AVG
+27.10%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+20366.53%
vs the sector median at left
Niki BioSolutions, Inc.
Market Cap
$381940.00
Debt to Assets Ratio
18.42%
TTM Avg
19.49%
3Y Avg
18.79%
5Y Avg
14.49%
Market Cap
$354588.00
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$484571.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$526055.00
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$552749.00
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108688.00
Debt to Assets Ratio
0.33%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$96236.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niki BioSolutions, Inc. (NIKI) | $381940.00 | 18.42% | 19.49% | 18.79% | 14.49% |
| Virax Biolabs Group Limited (VRAX)vs › | $354588.00 | 0.05% | N/A | N/A | N/A |
| XORTX Therapeutics Inc. (XRTX)vs › | $484571.00 | 0.00% | N/A | N/A | N/A |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | 0.05% | N/A | N/A | N/A |
| VivoSim Labs, Inc. (VIVS)vs › | $526055.00 | 0.08% | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $552749.00 | 0.25% | N/A | N/A | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $108688.00 | 0.33% | N/A | N/A | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $96236.00 | 0.00% | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $685871.00 | 0.38% | N/A | N/A | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $70876.00 | 0.00% | N/A | N/A | N/A |
Debt/Assets
18.4%
Debt/Equity
0.15
Current Ratio
0.78
Interest Coverage
-19.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2025-12-31 | 18.42% |
| 2025-09-30 | 19.49% |
| 2025-06-30 | 19.25% |
| 2024-12-31 | 20.80% |
| 2024-06-30 | 19.09% |
| 2023-12-31 | 16.90% |
| 2023-06-30 | 3.50% |
| 2022-12-31 | 32.85% |
| 2022-06-30 | 14.68% |
| 2021-12-31 | 0.99% |
| 2021-06-30 | 4.96% |
| 2020-12-31 | 2.99% |
| 2020-06-30 | 13.62% |
| 2019-12-31 | 27.03% |
| 2019-06-30 | 0.67% |
| 2018-12-31 | 22.84% |
| 2018-06-30 | 38.34% |
